Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | WRN | Q14191 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 7/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098396 | 0.88 | MGLL (0.50) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL14984834 | 0.85 | PTGS1 (0.49) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL5165325 | 0.85 | GSK3A (0.68) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL1230250 | 0.83 | ALDH1A1 (0.52) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL5826261 | 0.83 | MGLL (0.46) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL31084132 | 0.82 | CYP2C19 (0.61) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL12021170 | 0.82 | MGLL (0.44) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL5160607 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL4618418 | 0.82 | ALDH1A1 (0.50) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL14014719 | 0.80 | MGLL (0.43) | ALDH1A1HPGDCYP1A2CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| CN-115003803-A | Monomeric proteins and products for hydroxylated amino acids | 现代牧场股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-1856146-B1 | FGF GROWTH FACTOR ANALOGS | FERRING BV (NL) | 2019-05-29 | — | — | EP | disclosed |
| US-8227411-B2 | FGF growth factor analogs | BioSurface Engineering Technologies, Incle (US) | 2012-07-24 | — | — | US | disclosed |
| US-7528105-B1 | Heterodimeric chain synthetic heparin-binding growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090111743-A1 | Cysteine-branched heparin-binding growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| EP-1856146-A2 | FGF GROWTH FACTOR ANALOGS | Biosurface Engineering Technologies, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006093814-A2 | FGF GROWTH FACTOR ANALOGS | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199764-A1 | FGF growth factor analogs | BIOSURFACE ENGINEERING TECHNOLOGIES, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1019371-B1 | DIMALEINIMIDO-SUBSTITUTED DIHYDROXYALKANES WHICH CAN BE USED AS CROSSLINKING REAGENTS AND PROCESS FOR THEIR PREPARATION | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-5912359-A | Dimaleinimido-substituted dihydroxyalkanes which can be used as crosslinking reagents and process for their preparation | FORSCHUNGSZENTRUM JULICH GMBH (DE) | 1999-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | ALDH1A1 4643/4885HPGD 4028/4885CYP1A2 4859/4885 |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | ALDH1A1 4643/4885HPGD 4028/4885CYP1A2 4859/4885 |
| US-20090111743-A1 | Cysteine-branched heparin-binding growth factor analogs | HDGF, IGFBP1, IGFBP4 | ALDH1A1 2571/4885HPGD 1708/4885CYP1A2 4737/4885 |
| US-20060199764-A1 | FGF growth factor analogs | FGF2, FGF1, FGFR1 | ALDH1A1 2944/4885HPGD 2343/4885CYP1A2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.